Nkarta, Inc. announced that it will present preliminary data from its Phase 1 dose escalation clinical trial of NKX019 at two upcoming scientific conferences in June 2023: the European Hematology Association (EHA) 2023 Hybrid Congress and the 17th International Conference on Malignant Lymphoma (17-ICML). NKX019 is an allogeneic, off-the-shelf cell therapy candidate comprising NK cells derived from healthy donors and engineered to target the B-cell antigen CD19. The purpose of the presentations is to ensure that clinical investigators and the broader clinical community have the opportunity to assess the NKX019 clinical data from the November 2022 data cut-off in a peer-reviewed format.

These data were previously disclosed at a company event in December 2022. Nkarta continues to plan to present an update to these data later in 2023.